Background The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal
cell carcinoma (mRCC) remains unclear in the immuno-oncology (IO) era. Currently, only …

403 Background: The CARMENA study found no survival benefit from cytoreductive
nephrectomy (CN) in poor-risk metastatic renal cell cancer (mRCC) patients treated with first …

Upfront cytoreductive nephrectomy (CN) was the standard treatment for selected patients
with metastatic Renal Cell Carcinoma (RCC) in the cytokine era for many years. In the recent …

Background: The landscape of metastatic renal cell carcinoma (mRCC) treatment has
witnessed significant transformations with the emergence of immunotherapy-based …

Initial cytoreductive nephrectomy (CN) became the standard of care for metastatic renal cell
carcinoma (mRCC) because of a survival benefit in the interferon era [1, 2]. Since then …

Background and objective The role of cytoreductive nephrectomy (CN) in the treatment of
metastatic renal cell carcinoma (mRCC) has been called into question on the basis of …

359 Background: The advent of ICIs has dramatically changed the treatment paradigm in
mRCC. Although CN was demonstrated to improve survival in combination with cytokine …

Background: It is unknown whether previously reported other-cause mortality (OCM)
advantage of partial cytoreductive nephrectomy (PCN) vs. radical cytoreductive …

Immunotherapy-based systemic treatment (ST) is the standard of care for most patients
diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) …

Introduction While there are a plethora of studies supporting novel treatment approaches in
metastatic clear cell renal cell carcinoma (ccRCC), much of the data used to inform care of …